Patents by Inventor Peter Schulz-Knappe
Peter Schulz-Knappe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11860162Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.Type: GrantFiled: July 6, 2020Date of Patent: January 2, 2024Assignee: Oncimmune Germany GmbHInventors: Angelika Luking, Peter Schulz-Knappe, Carmen Theek, Petra Budde, Anna Telaar
-
Patent number: 11609237Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.Type: GrantFiled: December 4, 2019Date of Patent: March 21, 2023Assignee: ONCIMMUNE GERMANY GMBHInventors: Petra Budde, Peter Schulz-Knappe, Angelika Luking, Martin Gamer
-
Patent number: 11320438Abstract: Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.Type: GrantFiled: October 31, 2016Date of Patent: May 3, 2022Assignees: ELECTROPHORETICS LIMITED, RUPRECHT-KARLS-UNIVERSITAT, DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Sasa Koncarevic, Karsten Kuhn, Peter Schulz-Knappe, Ian Hugo Pike, Christiane Opitz, Michael Platten
-
Publication number: 20210231663Abstract: Biomarkers are provided for predicting an irAE response associated with administration of anti-CTLA-4 antibodies (i.e. ipilumamb) and antibodies disrupting the PD-1/PD-L1 pathway (i.e. nivolumab or pembrolizumab) for treating melanoma. Methods of treatment incorporating such biomarkers are also provided.Type: ApplicationFiled: December 10, 2018Publication date: July 29, 2021Applicant: ONCIMMUNE GERMANY GMBHInventors: Petra BUDDE, Peter SCHULZ-KNAPPE, Hans-Dieter ZUCHT
-
Patent number: 10976321Abstract: Provided is a method of assaying for an analyte, including combining a test sample having the analyte, with a calibration sample having at least two different aliquots of the analyte, each aliquot having a different known quantity of the analyte. The test sample and each aliquot are differentially labeled with one or more isobaric mass labels each with a mass spectrometrically distinct mass marker group, such that the test sample and each aliquot of the calibration sample can be distinguished by mass spectrometry. The method further includes determining by mass spectrometry the quantity of analyte in the test sample and in each aliquot, and calibrating the quantity of analyte in the test sample against known and determined quantities of analytes in the aliquots.Type: GrantFiled: January 23, 2017Date of Patent: April 13, 2021Assignee: ELECTROPHORETICS LIMITEDInventors: Peter Schulz-Knappe, Ian Pike, Karsten Kuhn
-
Publication number: 20210055296Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.Type: ApplicationFiled: July 6, 2020Publication date: February 25, 2021Applicant: Oncimmune Germany GmbHInventors: Angelika LUKING, Peter SCHULZ-KNAPPE, Carmen THEEK, Petra BUDDE, Anna TELAAR
-
Publication number: 20210003590Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.Type: ApplicationFiled: December 4, 2019Publication date: January 7, 2021Applicant: Oncimmune Germany GmbHInventors: Petra BUDDE, Peter SCHULZ-KNAPPE, Angelika LUKING, Martin GAMER
-
Patent number: 10746735Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.Type: GrantFiled: February 10, 2015Date of Patent: August 18, 2020Assignee: Oncimmune Germany GmbHInventors: Angelika Lüking, Peter Schulz-Knappe, Carmen Theek, Petra Budde, Anna Telaar
-
Publication number: 20200150117Abstract: The invention relates to a method of identifying a tumor-associated antigen (TAA) for prostate cancer. Moreover, the invention provides a method of identifying a TAA as a marker for prostate cancer vaccination response. Particularly, a method of identifying and treating a prostate cancer patient with PROSTVAC therapy or for vaccination with a prostate antigen.Type: ApplicationFiled: June 23, 2018Publication date: May 14, 2020Inventors: Hans-Dieter ZUCHT, Petra BUDDE, Peter SCHULZ-KNAPPE
-
Patent number: 10571477Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.Type: GrantFiled: July 4, 2015Date of Patent: February 25, 2020Assignee: Protagen GmbHInventors: Petra Budde, Peter Schulz-Knappe, Angelika Lüking, Martin Gamer
-
Publication number: 20190128884Abstract: The present invention relates to a method for managing the therapy of patients and patient (sub)populations (responder/non-responder) suffering from rheumatoid arthritis (RA) and to the use of suitable marker sequences, in particular in the form of panels, diagnostic agents and test kits, and to their use in rheumatoid arthritis (RA) diagnosis, prognosis and therapy management, in particular for drug-based therapy.Type: ApplicationFiled: June 15, 2017Publication date: May 2, 2019Inventors: Petra BUDDE, Angelika LÜKING, Peter SCHULZ-KNAPPE, Hans-Dieter ZUCHT
-
Publication number: 20190120834Abstract: The present invention relates to a novel method for identifying marker sequences for rheumatoid arthritis, the novel marker sequences discovered with the aid of the method, and the diagnostic use thereof. The invention also relates to diagnostic devices containing such marker sequences for rheumatoid arthritis, in particular a protein biochip or beads (pellets), and use thereof.Type: ApplicationFiled: April 3, 2017Publication date: April 25, 2019Inventors: Angelika LÜKING, Petra BUDDE, Peter SCHULZ-KNAPPE, Dieter ZUCHT
-
Publication number: 20180246118Abstract: Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.Type: ApplicationFiled: October 31, 2016Publication date: August 30, 2018Applicants: ELECTROPHORETICS LIMITED, RUPRECHT-KARLS-UNIVERSITÄT, DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Sasa Koncarevic, Karsten Kuhn, Peter Schulz-Knappe, Ian Hugo Pike, Christiane Opitz, Michael Platten
-
Patent number: 10060911Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterization and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.Type: GrantFiled: August 18, 2012Date of Patent: August 28, 2018Assignee: Protagen AktiengesellschaftInventors: Stefan Müllner, Peter Schulz-Knappe, Angelika Lueking, Heike Göhler, Jessica Schwermann
-
Publication number: 20170199202Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.Type: ApplicationFiled: July 4, 2015Publication date: July 13, 2017Inventors: Petra BUDDE, Peter SCHULZ-KNAPPE, Angelika LÜKING, Martin GAMER
-
Publication number: 20170146544Abstract: Provided is a method of assaying for an analyte, including combining a test sample having the analyte, with a calibration sample having at least two different aliquots of the analyte, each aliquot having a different known quantity of the analyte. The test sample and each aliquot are differentially labeled with one or more isobaric mass labels each with a mass spectrometrically distinct mass marker group, such that the test sample and each aliquot of the calibration sample can be distinguished by mass spectrometry. The method further includes determining by mass spectrometry the quantity of analyte in the test sample and in each aliquot, and calibrating the quantity of analyte in the test sample against known and determined quantities of analytes in the aliquots.Type: ApplicationFiled: January 23, 2017Publication date: May 25, 2017Applicant: Electrophoretics LimitedInventors: PETER SCHULZ-KNAPPE, Ian Pike, Karsten Kuhn
-
Publication number: 20170074875Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.Type: ApplicationFiled: February 10, 2015Publication date: March 16, 2017Inventors: Angelika LÜKING, Peter SCHULZ-KNAPPE, Carmen THEEK, Petra BUDDE, Anna TELAAR
-
Patent number: 9470692Abstract: The disclosure provides a method for assaying for a target analyte, comprising providing a plurality of samples which may comprise the target analyte, wherein each sample is differentially labelled with a mass label or a combination of mass labels, wherein the mass labels are from a set of mass labels, wherein each mass label is an isobaric mass label comprising a mass spectrometrically distinct mass marker group, such that the samples can be distinguished by mass spectrometry and determining from the mass spectrum the quantity of the target analyte in each sample.Type: GrantFiled: May 18, 2009Date of Patent: October 18, 2016Assignee: ELECTROPHORETICS LIMITEDInventors: Christian Baumann, Helen Byers, Peter Schulz-Knappe, Malcolm Ward
-
Publication number: 20150323529Abstract: The present invention relates to new markers for Neuromyelitis Optica (NMO), a method for identifying markers for NMO, the use of the markers identified by the method, diagnostic devices, panels of markers, assays, protein arrays comprising markers for NMO and a method for detecting NMO.Type: ApplicationFiled: November 27, 2013Publication date: November 12, 2015Inventors: Heike GÖHLER, Marquart KLAUS, Andrew CHAN, Peter SCHULZ-KNAPPE, Carmen THEEK, Anna TELAAR, Martin GAMER
-
Publication number: 20150293120Abstract: The present invention relates to a novel method for identifying marker sequences for rheumatoid arthritis, the novel marker sequences discovered with the aid of the method, and the diagnostic use thereof. The invention also relates to diagnostic devices containing such marker sequences for rheumatoid arthritis, in particular a protein biochip or beads (pellets), and use thereof.Type: ApplicationFiled: March 27, 2013Publication date: October 15, 2015Inventors: Angelika LÜKING, Peter SCHULZ-KNAPPE, Heike GÖHLER, Martin GAMER, Carmen THEEK, Daniel CHAMRAD, Anna TELAAR, Matthias VON DARL, Matthias SCHNEIDER, Jessica SCHWERMANN